

Altered splicing in exon 8 of the DNA replication factor CIZ1 affects subnuclear distribution and is associated with Alzheimer's disease

Dahmcke, Christina Mackeprang; Büchmann-Møller, Stine; Nielsen, Niels Aagaard; Mitchelmore, Cathy

Published in:
Molecular and Cellular Neuroscience

DOI:
[10.1016/j.mcn.2008.05.007](https://doi.org/10.1016/j.mcn.2008.05.007)

Publication date:
2008

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Dahmcke, C. M., Büchmann-Møller, S., Nielsen, N. A., & Mitchelmore, C. (2008). Altered splicing in exon 8 of the DNA replication factor CIZ1 affects subnuclear distribution and is associated with Alzheimer's disease. *Molecular and Cellular Neuroscience*, 38(4), 589-594. <https://doi.org/10.1016/j.mcn.2008.05.007>


General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact rucforsk@kb.dk providing details, and we will remove access to the work immediately and investigate your claim.



Altered splicing in exon 8 of the DNA replication factor CIZ1 affects subnuclear distribution and is associated with Alzheimer's disease

Christina Mackeprang Dahmcke^a, Stine Büchmann-Møller^b, Niels A. Jensen^c, Cathy Mitchelmore^{a,*}

^a Eucaryotic Cell Biology Research Group, Department of Science, Roskilde University, Roskilde, Denmark

^b Institute of Cell Biology, Zurich University, 8093, Switzerland

^c Molecular Neurobiology Laboratory, Medical Biotechnology Center, University of Southern Denmark, J.B. Winslowsvej 25, Odense C, Denmark

ARTICLE INFO

Article history:

Received 14 February 2008

Revised 5 May 2008

Accepted 7 May 2008

Available online 20 May 2008

Keywords:

CDKN1A

Nuclear matrix

Alzheimer's disease

DNA replication

ABSTRACT

In order to understand the gene-mediated processes underlying sporadic Alzheimer's disease (AD), we carried out a subtractive cloning screen for novel AD candidate genes. We identified the gene encoding the DNA replication factor CIZ1 (CDKN1A interacting zinc finger protein 1) as being more highly expressed in Alzheimer tissue than in healthy brains. We show here that an isoform of CIZ1 which lacks a glutamine-rich region, due to alternative splicing in exon 8, is upregulated in AD brains relative to the full-length CIZ1 protein. We demonstrate for the first time that a minimal 28 amino acid sequence within this region is required for CIZ1 to associate with the nuclear matrix and to form nuclear foci.

© 2008 Elsevier Inc. All rights reserved.

Introduction

Alzheimer's Disease (AD) is a debilitating disease, characterised by the progressive loss of memory and cognitive abilities. Neuropathologically, the disorder is associated with the extracellular deposition of β -amyloid aggregates in senile plaques and the intracellular accumulation of neurofibrillary tangles. These changes lead to the loss of synaptic function and neuronal cell death in specific brain regions (Terry et al., 1999). The first regions affected by neuronal loss and AD pathology include the entorhinal cortex and the CA1 subregion of the hippocampus (Braak and Braak, 1991; Gomez-Isla et al., 1996; West et al., 1994). Since these regions are essential for the flow and integration of information through the hippocampus, this explains why the early symptoms of AD are related to defective memory (Eichenbaum, 2001; Morris, 1999).

Genetically inherited mutations which lead to early-onset AD (onset before the age of 60) have so far been identified in three genes: amyloid precursor protein, presenilin 1 and presenilin 2 (Price and Sisodia, 1998; Sisodia et al., 1999). However, early-onset AD comprises only about 5% of AD cases. The majority of AD cases are late-onset (after 65 years of age), and occur sporadically. Several genetic risk factors have been described for the late-onset form of AD, notably the $\epsilon 4$ allele of the apolipoprotein E gene (Corder et al., 1993; Farrer et al.,

1997; Saunders et al., 1993), but the precise etiology of sporadic AD is poorly understood.

Several reports have indicated that the inappropriate re-entry of post-mitotic neurons into the cell cycle may lead to disruption of cell function in AD (Nagy, 2000; Zhu et al., 2006). In addition to elevated levels of cell cycle proteins, there is evidence that AD-affected neurons have passed the G1/S-checkpoint and initiated DNA replication (Vincent et al., 1997; Yang et al., 2001, 2003). CDKN1A (p21Cip1) is a major factor in blocking the onset of S phase. CIZ1 was first isolated in a yeast two-hybrid screen for cyclin E/CDKN1A interaction partners and shown to bind to CDKN1A (Mitsui et al., 1999). It was proposed that CIZ1 regulates entry into S phase by inducing the cytoplasmic export of CDKN1A (Mitsui et al., 1999). CIZ1 contains two glutamine-rich domains in the N-terminal end, and three zinc fingers in the C-terminal end which are capable of binding to DNA (Mitsui et al., 1999; Warder and Keherly, 2003). Murine Ciz1 has been shown to stimulate DNA replication in NIH3T3 cells. Consistent with a role in DNA replication, Ciz1 forms nuclear speckles, and colocalises with PCNA in replication foci during S phase (Coverley et al., 2005).

There is currently no effective therapy preventing cell loss in AD. Identification of genes whose expression is altered during the beginning stages of the disease should aid in identifying molecules that are potential targets for therapy and lead to a better understanding of the disease process. Using a subtractive cloning approach, we previously reported the identification of NDRG family member 2 (NDRG2) as a protein upregulated in AD and associated with AD pathology (Mitchelmore et al., 2004). Here, we describe additional candidate genes, isolated in the same screen, which are upregulated in AD. Of these, the gene encoding CDKN1A interacting zinc finger protein 1

Abbreviations: CIZ1, CDKN1A interacting zinc finger protein 1; CDKN1A, Cyclin-dependent kinase inhibitor 1A (p21Cip1); AD, Alzheimer's disease; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; NDRG2, NDRG family member 2; GFAP, glial fibrillary acidic protein.

* Corresponding author. Fax: +45 46743011.

E-mail address: mitch@ruc.dk (C. Mitchelmore).




Fig. 1. Expression analysis of AD candidate genes on a slot blot. Plasmid DNA containing the indicated cDNAs were slot-blotted onto a membrane in duplicate. The membrane was cut in half and probed separately with radioactively labeled cDNA from either normal adult hippocampus (left) or AD hippocampus (right). Results were quantified by phosphorimager analysis and normalised to *GAPDH*. Eleven genes were found to be upregulated by at least 2-fold in this assay (starred).

(*CIZ1*), was selected for further study, due to its known role as a DNA replication factor.

Results

Identification of genes upregulated in AD brains

Using a subtractive cloning technique to detect candidate genes upregulated in the hippocampal region of AD brains, we previously isolated a total of 42 cDNAs (Mitchellmore et al., 2004). In order to test the remaining uncharacterised candidate genes for upregulation, we used a slot blot approach where plasmid DNA containing cDNA inserts were separately hybridised with labelled cDNA probe prepared from either control or AD hippocampus mRNA (Fig. 1). Changes in gene expression that are related to AD are expected to be highest in the

hippocampus, which is one of the brain regions most affected by AD pathology (Braak and Braak, 1991; West et al., 1994). *GAPDH* mRNA levels are unchanged in AD, allowing its use as a normalisation control (Gutala and Reddy, 2004). After normalisation of the signal to *GAPDH*, we identified 10 new candidate genes whose expression was upregulated in AD by more than 2-fold compared to control hippocampus. Upregulation of the mRNAs for *NDRG2* and *GFAP* in AD confirms our previous results (Mitchellmore et al., 2004), whereas upregulation of the polyadenylated form of mitochondrial 16S ribosomal RNA (*MTRNR2*) is probably a result of the increased mitochondrial DNA observed in AD (Hirai et al., 2001). Polyadenylation of the mitochondrial 16S ribosomal RNA and highly related cDNAs have previously been observed (Baserga et al., 1985; Guo et al., 2003). The results of the slot blot should be considered semiquantitative, due to variations inherent in any hybridization reaction, the high complexity of cDNA probes, and to detection limitations for low abundance genes (Wang and Brown, 1991).

In order to confirm the slot blot results, we selected two of the novel AD candidates to determine expression levels in human brain RNA distinct from that used in the subtractive cloning. In contrast to the slot blot, northern blotting was carried out on whole brain RNA. By northern blotting, we showed a modest (25% and 23%, respectively) increase in the mRNA levels for *EFNA3* and *CIZ1*, respectively, in AD compared to normal brain (data not shown). Since inappropriate entry into the cell cycle may play a role in AD (Nagy, 2000) and *CIZ1* can act as a DNA replication factor (Coverley et al., 2005), we decided to examine *CIZ1* tissue expression and cellular localisation in more detail.

Differential expression of *CIZ1* splice forms in AD brain

CIZ1 mRNA expression was examined in normal and AD afflicted tissue as well as in a range of human tissues and cell lines by PCR amplification of the region surrounding exon 8. As shown in Fig. 2, the splice variant *CIZ1S*, which contains a 168 nt deletion in exon 8, is upregulated in AD compared to normal hippocampi, taking into consideration the different levels of *GADPH*, used for normalisation, in the two tissues. Quantification of the data in Fig. 2 shows that levels of the full-length *CIZ1* are unaltered in AD, whereas expression of the splice variant *CIZ1S* is upregulated 2.5-fold in AD compared to normal hippocampus, after normalisation to *GADPH*. As expected, *GFAP* expression is increased in AD compared to normal hippocampus, by 5.6-fold, due to astrogliosis (Diedrich et al., 1987).

In AD hippocampus, *CIZ1S* expression is comparable to that of full-length *CIZ1*. In contrast, expression of *CIZ1S* is distinctly lower than the full-length transcript in all the examined normal tissues and cell lines. Amongst the cell lines, *CIZ1* was more highly expressed in the Ad5-transformed HEK293 and MCF7 cell lines, and was undetectable in the U118 glioblastoma cell line. Alternative splicing in exon 8 results in the in-frame removal of 56 amino acids (*CIZ1S*) or 28 amino acids




Fig. 2. Altered expression of *CIZ1S* is observed in AD hippocampus. PCR was used to examine alternative splicing of exon 8 in AD hippocampus, normal tissues and cell-lines. With the exception of AD, the short *CIZ1S* splice form was expressed at a lower level than the full-length *CIZ1* form in all samples. HF, hippocampus.

(CIZ1M) in the second glutamine-rich domain (Fig. 3). However, transcripts with the shorter deletion in exon 8 were not detected, probably due to a very low mRNA expression.

Association of CIZ1 with the nuclear matrix requires a glutamine-rich domain

In order to examine the importance of alternative splicing in exon 8 for the subcellular localisation of CIZ1 protein, we attempted to amplify the coding region of CIZ1 from hippocampus and cerebellum, where both CIZ1 and CIZ1S are expressed (see Fig. 2). However, we were unable to clone the coding region of CIZ1S, although we did obtain clones for both CIZ1 and CIZ1M. Mouse N2A neuroblastoma cells were therefore transfected with expression plasmids for full-length CIZ1 and the shorter isoform CIZ1M (Fig. 3A).

Cell lysates were separated into four fractions: soluble proteins, two fractions of chromatin-bound proteins, and proteins bound to the nuclear matrix. Both CIZ1 and CIZ1M proteins appeared in the soluble fraction and the DNase-treated chromatin fraction. However, the majority of full-length CIZ1 protein was recovered in the nuclear matrix fraction. Deletion of 28 amino acids in the glutamine-rich Q2-region almost completely abrogated association of CIZ1M with the nuclear matrix (Fig. 3B).

In accordance with the fractionation results, immunofluorescent staining of the transfected cells showed that full-length CIZ1 protein appeared in speckles which resemble replication foci (Figs. 4A–C). However, in some cells CIZ1 appeared to be localized mainly in the cytoplasm, where it might be sequestered when it is not involved in DNA replication (Figs. 4D–F). The smaller splice variant CIZ1M did not form the speckled pattern, but instead it localized solely in the nucleus in a diffuse pattern (Figs. 4G–I). Therefore, the region lacking in CIZ1M seems to be important for the location and appearance of CIZ1 in the

cell. Since this region is also lacking in the CIZ1S variant, it is likely that the pattern of CIZ1S resembles that shown here for CIZ1M.

Discussion

In this study, we demonstrate the altered processing of CIZ1 mRNA in the hippocampus of AD patients. This results in the upregulation of an alternatively spliced form of CIZ1, in which the encoded protein lacks a glutamine-rich domain. This smaller transcript, CIZ1S, is present as a minor component in a range of normal tissues and cancer cell lines, suggesting that the ratio of CIZ1S to the full-length CIZ1 is normally regulated. Misregulation of alternative splicing has previously been reported for sporadic AD, including exon 5 skipping for the *Presenilin-2* transcript and exon 10 inclusion in the *Tau* transcript (Glatz et al., 2006; Manabe et al., 2003). Misregulation of splicing in AD may be a result of genetic mutations in the gene itself or reflect changes in the regulators of splicing, for example as a result of hypoxic stress (Manabe et al., 2003). In the case of CIZ1S, a 168 nt region located centrally in exon 8 is spliced out. Although the “intron” conforms to the GT–AG rule, there is no polypyridine tract, and the mechanism regulating alternative splicing in exon 8 is unclear.

Our results demonstrate that the majority of full-length human CIZ1 protein is bound to the nuclear matrix, following extraction with nuclease and high salt. Accordingly, our immunofluorescent staining revealed the localisation of CIZ1 in nuclear speckles. This is in agreement with results obtained with endogenous mouse Ciz1, in which nuclear-matrix-associated Ciz1 is present in replication foci (Ainscough et al., 2007). Our observation that some CIZ1 is released by nuclease treatment is consistent with the role of CIZ1 as a DNA-binding protein (den Hollander et al., 2006; Warder and Keherly, 2003). Furthermore, we observe a proportion of CIZ1 in the soluble fraction, consistent with reports that mouse Ciz1 is present in the nucleus as both a soluble and a detergent-resistant fraction (Coverley et al., 2005). We also observe formation of CIZ1 aggregates in the cytosol of some transfected cells. This may result from self-aggregation of CIZ1, due to its glutamine-rich domains, or to the cytoplasmic sequestration by CIZ1 of cell cycle proteins such as CDKN1A (Mitsui et al., 1999).

Alternative splicing in CIZ1S results in the removal of amino acids 379–434 in the second glutamine-rich domain. Deletion of a corresponding region by alternative splicing has been reported in the embryonic form of mouse Ciz1, called ECiz1 (Coverley et al., 2005) (Fig. 3). We used a transcript with a shorter deletion within exon 8 in cell transfection studies, in order to delineate the role of this region in CIZ1 localisation, since we were unable to clone CIZ1S by PCR. The 28 amino acid region lacking in CIZ1M is also lacking in CIZ1S, and therefore we postulate that the appearance and localisation of CIZ1S resembles that of CIZ1M. However, we cannot exclude the possibility that the larger deletion in CIZ1S, removing 56 amino acids in the glutamine-rich domain of CIZ1, causes additional changes in protein localisation. The CIZ1M variant, lacking amino acids 407–434, showed a disruption of the speckled pattern, and instead a diffuse localization in the nucleus was observed. Furthermore, the CIZ1M protein was readily extracted into the soluble and chromatin fractions, and only weakly associated with the nuclear matrix in our fractionation studies. Ainscough and others carried out immunofluorescence staining with NIH3T3 cells and GFP-tagged ECiz1 (Ainscough et al., 2007). They demonstrated that ECiz1 is less efficiently concentrated in nuclear foci than full-length Ciz1. However, in contrast to our results with CIZ1M, they showed that GFP-ECiz1 resists extraction with detergent and nuclease/high-salt, indicating attachment to the nuclear matrix. They conclude that sequences in the C-terminal third of Ciz1 are responsible for immobilization on the nuclear matrix. However, these results cannot be directly compared to ours, because they use a GFP tag and a milder 0.5 M NaCl extraction, either of which may affect subnuclear attachment.




Fig. 3. (A) The structure of full-length CIZ1 is shown. The residues lacking in the human splice variants CIZ1M and CIZ1S, due to alternative splicing in exon 8, are indicated. The 168 bp deletion is present in cDNAs with accession nos. BC021163 and AK023976; the shorter 84 bp deletion is present in BC004119 and CIZ1M (this study). For comparison, the homologous region deleted in the mouse ECiz1 isoform (Coverley et al., 2005), due to alternative splicing, is shown. (B) Western blot of V5-tagged CIZ1 (left panel) and CIZ1M (right panel) in fractions obtained from transfected cells: soluble proteins (nuclear and cytoplasmic), chromatin-bound proteins (DNase- or NaCl-released) and nuclear matrix-bound proteins. The proteins lamin A/C, α -tubulin and histone H3 are released in different fractions and demonstrate the purity of the fractions. The majority of the full-length CIZ1 is present in the nuclear matrix, whereas CIZ1M is mostly present in the soluble and chromatin fractions. The results are representative of three independent experiments.




Fig. 4. Subcellular localization of V5-tagged CIZ1 isoforms. Staining for the full-length variant of CIZ1 showed a speckled pattern, localized in varying patterns: in the nucleus (A), cytosol (D) or both (not shown). The CIZ1M variant lacking part of the second polyglutamine domain was diffusely distributed throughout the nucleus (G). (A, D, G) V5 staining; (B, E, H) DAPI staining; (C, F, I) merged images.

Two main species of CIZ1 protein are observed in nontransfected cells: 95 and 120 kDa in human, and 100 and 125 kDa in mouse cells (Coverley et al., 2005; Mitsui et al., 1999). In human U2-OS cells, the 95 kDa species is detergent-soluble whereas the 120 kDa form of CIZ1 fractionates in the NP-40 resistant cell pellet (Mitsui et al., 1999). However, in NIH3T3 cells, the p100 form of Ciz1, but not the p125 form, is resistant to 2 M NaCl extraction, suggesting a stronger association of the p100 form with subnuclear structures (Ainscough et al., 2007). These differences may reflect the different detergent treatments and cell lines used. It may also suggest that there are differences in the behaviour of mouse and human CIZ1, which share only about 70% homology. The relation between the 95 and 120 kDa protein species is currently unclear. However, the larger 120 kDa species behaves like full-length CIZ1 does in our hands, whereas the 95 kDa protein in human cells and CIZ1M are both detergent-soluble. The 28 amino acid region lacking in CIZ1M is also lacking in CIZ1S, and therefore we postulate that CIZ1M and CIZ1S behave similarly. Thus, the 95 kDa form may arise from alternative splicing in exon 8 and thereby generating an isoform lacking part of the second glutamine-rich domain, corresponding to either CIZ1M or CIZ1S.

We demonstrate for the first time that human CIZ1 associates with the nuclear matrix. Furthermore, we report that in human CIZ1, amino acids 407–434 affect the formation of speckles and attachment to the nuclear matrix. Since this exon 8-encoded region is also lacking in the CIZ1S variant, we postulate that the appearance and localisation of CIZ1S resembles that of CIZ1M. Mouse ECiz1 retains the ability to promote DNA replication, suggesting that exon 8 is not required for this basic function (Coverley et al., 2005). There are 4 binding regions for CDKN1A on CIZ1: one between the two glutamine-rich domains,

two in the zinc finger region, and one in the C-terminal end (Mitsui et al., 1999). Since these regions are outside of the regions deleted in CIZ1M and CIZ1S, it is likely that CIZ1M and CIZ1S also bind to

Table 1

Description of the cDNAs isolated in a screen for AD-upregulated genes and analysed by slot blot

Gene	mRNA	Insert*	Full name	Accession no.
<i>EFNA3</i>	1798 nt	1.8 kb	Ephrin-A3	NM_004952
<i>MAPT</i>	5464 nt	570 bp	Microtubule-associated protein tau	NM_016841
<i>SRP72</i>	3852 nt	2 kb	Signal recognition particle 72 kDa	NM_006947
<i>SEPT5</i>	2079 nt	1.8 kb	Septin 5	BC025261
<i>CIZ1</i>	3032 nt	2.1 kb	CDKN1A interacting zinc finger protein 1	NM_012127
<i>ATRNL1</i>	8645 nt	1.8 kb	Attractin	NM_139321
<i>HTRA1</i>	2133 nt	2.1 kb	HtrA serine peptidase	NM_002775
<i>MTRNR2</i>	1558 nt	600 bp	Mitochondrial 16S rRNA	EU369395
<i>RGL1</i>	5113 nt	2.8 kb	Ral guanine nucleotide dissociation stimulator-like 1	NM_015149
<i>JARID1A</i>	6455 nt	1.8 kb	Jumonji, AT rich interactive domain 1A	NM_005056
<i>NELF</i>	2972 nt	2.9 kb	Nasal embryonic LHRH factor	NM_015537
<i>AUTS2</i>	5972 nt	1.7 kb	Autism susceptibility candidate 2	NM_015570
<i>HSP90AA1</i>	2912 nt	2.9 kb	Heat shock protein 90 kDa alpha (cytosolic), class A member 1	NM_005348
<i>VSNL1</i>	2014 nt	2.2 kb	Visinin-like 1	NM_003385
<i>PLP1</i>	3038 nt	3 kb	Proteolipid protein 1	NM_000533
<i>GLUL</i>	2778 nt	2.7 kb	Glutamate-ammonia ligase	BC011700
<i>HSPA8</i>	2276 nt	2.1 kb	Heat shock 70 kDa protein 8	NM_006597

*All cDNA inserts contained a 3' poly-A tail, except *SRP72*, *RGL1*, *JARID1A* (due to mispriming at an internal A-rich sequence) and *CIZ1* (due to cleavage at an internal NotI site).

CDKN1A. Ciz1 is proposed to play a role in replication factory formation, by tethering replication factories to the nuclear matrix (Ainscough et al., 2007). Thus, assembly of CIZ1 into nuclear foci is likely to be important for regulated entry into the S-phase of the cell cycle. The increased expression of CIZ1S compared to CIZ1 in AD may therefore be expected to contribute to dysregulation of cell cycle control.

Experimental methods

Slot blot

A 1 kb PCR product for human *GAPDH* cDNA was cloned into the pCR-TOPO vector (Invitrogen). The other plasmids used in the slot blot, containing cDNA inserts in the pZL1 plasmid (Invitrogen), were isolated in a subtractive screen for genes upregulated in AD (Mitchelmore et al., 2004; Table 1). Plasmid DNA (1 µg) was denatured in 0.3 M NaOH for 10 min at 68 °C, neutralised and bound in duplicate to a Hybond-XL membrane in a slot-blot vacuum apparatus. The membrane was cut in half and the duplicate blots were separately hybridised to radioactively labelled first-strand cDNA (100 ng) which had been prepared from either AD or control hippocampus RNA (Mitchelmore et al., 2004). To block non-specific binding, the hybridisation buffers contained 500 µg denatured salmon sperm DNA and 5 µg poly-dT₂₀, and the overnight hybridisation was carried out at 72 °C. Stringent hybridisation and wash conditions were used to reduce cross-hybridisation with related sequences. Bound label was quantified with a phosphorimager.

RT-PCR

cDNA synthesis on U118 mRNA was performed using SuperScript III Reverse Transcriptase Kit (Invitrogen). First-strand cDNA from liver and colon, Marathon cDNA from cerebellum and hippocampus, and cDNA from a human cell line panel were all purchased from Clontech. The 25 µl PCR reaction contained 2.5 µl cDNA, 10 pmol each primer, 2.5 µl reaction buffer, 0.2 M dNTPs and 0.5 µl Advantage II Polymerase (Clontech). The PCR program was: 1 cycle at 94 °C; 5 cycles at 94 °C 30 s, 72 °C 2 min; 15–25 cycles at 94 °C 30 s, 68 °C 2 min; and 1 cycle at 68 °C 5 min.

The following primer pairs were used in PCR: *CIZ1* (5' GTACCGAAA-CAGACACAGACACCAGAC 3' and 5' AACCACTGTTGCTCTGGAG 3'); *GAPDH* (5' TGAAGGTCGGAGTCAACGCATTTGGT 3' and 5' CATGTGGCCATGAGGTCCACCAC 3'); and *GFAP* (5' TGACCTCTCCACC-CATAGTGAC 3' and 5' CTAATCTCAGGGCACTGCTGCTG 3'). The expected fragment sizes were: *GAPDH* 983 bp, *GFAP* 424 bp, *CIZ1* 585 bp, *CIZ1M* 501 bp and *CIZ1S* 417 bp. The identity of the PCR bands obtained for *CIZ1* were confirmed by sequencing.

Cell transfections

The coding region of *CIZ1* was obtained by PCR amplification from cerebellum cDNA and cloned into the pCDNA6/V5HisA vector (Invitrogen), in frame with the C-terminal V5-epitope. The inserts were completely sequenced, and shown to encode full-length CIZ1 as well as the CIZ1M splice variant. Mouse neuroblastoma (N2A) cells were grown in Dulbecco's modified Eagle's medium containing 10% FBS with penicillin/streptomycin. 2.5×10^5 cells/well were seeded in a 6-well plate, transfected with 4 µg DNA per well using Lipofectamine 2000 (Invitrogen), and harvested after 48 h.

Immunocytochemistry

2×10^4 cells were grown on coverslips in 24-well plates for 24 h before transfection, and then grown for 48 h before being fixed in cold methanol for 5 min. Cells were blocked in PBS containing 0.2% Triton

X-100 and 3% BSA and washed in PBS with 0.2% Triton X-100. Mouse anti-V5 antibody (Invitrogen) was diluted 1:400, incubated overnight on the coverslips in a humidity chamber at 4 °C, and was detected using Alexa Fluor 488 anti-mouse antibody. Coverslips were mounted onto slides using Vectashield mounting medium with DAPI (Vector). Images were collected using a Leica FW 4000 camera with a 100× oil objective.

Cell fractionation and western blots

The protocol is adapted from (Farley et al., 2006; He et al., 1990). Cell pellets were washed twice in PBS and centrifuged 5 min at 2000 rpm. The cell pellet was resuspended in cold cytoskeletal (CSK) buffer (20 mM PIPES (Sigma), 100 mM NaCl, 300 mM Sucrose, 3 mM MgCl₂, 1 mM EGTA (Sigma), protease inhibitor (1:500 v/v) (Sigma), 0.5% Triton X, pH 7), incubated at room temperature for 5 min and centrifuged 5 min at 2000 rpm. The supernatant was collected and labeled "Soluble fraction". This step was repeated once, and the pellet was resuspended in CSK buffer containing 250 U/ml DNase I (Roche) and incubated 15 min at 20 °C, followed by 20 min at 37 °C. Then (NH₄)₂SO₄ was added to give a final concentration of 0.25 M, and the samples were incubated 5 min on ice. Hereafter the samples were centrifuged at 8000 rpm for 5 min. The supernatant was collected and labeled "Chromatin DNase fraction". The pellet was then resuspended in CSK buffer containing 2 M NaCl, incubated 5 min on ice, and centrifuged 5 min at 13,000 rpm. The supernatant was collected and labeled "Chromatin NaCl fraction". The remaining pellet was resuspended in 8 M urea solution (8 M urea pH 8, 100 mM NaH₂PO₄, 10 mM Tris-HCl), and labeled "Nuclear Matrix fraction".

Protein concentration was measured using the Bradford assay. Proteins were separated on 4–12% Tris-Glycine SDS gels (Anamed), and transferred to PVDF membranes (GE Healthcare). Immunoblotting was performed using the West Dura kit (Pierce). Primary antibodies were diluted as follows: anti-V5 (1:20,000), mouse anti-α-tubulin and rabbit anti-histone H3 (1:10,000, Sigma); and rabbit anti-lamin A/C (1:4000, Cell Signaling Technology). Protein bands were detected using a Biospectrum AC imaging System (UVP).

Acknowledgments

This work was supported by grants from the Lundbeck Foundation, the Novo Nordisk Foundation, the Alfred Benzon Foundation, the Danish Cancer Society and the Danish Medical Research Council.

References

- Ainscough, J.F., Rahman, F.A., Sercombe, H., Sedo, A., Gerlach, B., Coverley, D., 2007. C-terminal domains deliver the DNA replication factor Ciz1 to the nuclear matrix. *J. Cell Sci.* 120, 115–124.
- Baserga, S.J., Linnenbach, A.J., Malcolm, S., Ghosh, P., Malcolm, A.D., Takeshita, K., Forget, B.G., Benz Jr., E.J., 1985. Polyadenylation of a human mitochondrial ribosomal RNA transcript detected by molecular cloning. *Gene* 35, 305–312.
- Braak, H., Braak, E., 1991. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–259.
- Corder, E.H., Saunders, A.M., Strittmatter, W.J., Schmechel, D.E., Gaskell, P.C., Small, G.W., Roses, A.D., Haines, J.L., Pericakvance, M.A., 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261, 921–923.
- Coverley, D., Marr, J., Ainscough, J., 2005. Ciz1 promotes mammalian DNA replication. *J. Cell Sci.* 118, 101–112.
- den Hollander, P., Rayala, S.K., Coverley, D., Kumar, R., 2006. Ciz1, a Novel DNA-binding coactivator of the estrogen receptor alpha, confers hypersensitivity to estrogen action. *Cancer Res.* 66, 11021–11029.
- Diedrich, J., Wietgreffe, S., Zupancic, M., Staskus, K., Retzel, E., Haase, A.T., Race, R., 1987. The molecular pathogenesis of astroglialosis in scrapie and Alzheimer's disease. *Microb. Pathog.* 2, 435–442.
- Eichenbaum, H., 2001. The hippocampus and declarative memory: cognitive mechanisms and neural codes. *Behav. Brain Res.* 127, 199–207.
- Farley, S.M., Chen, G., Guo, S., Wang, M., A. J., Lee, F., Lee, F., Sawicki, M., 2006. Menin localizes to chromatin through an ATR-CHK1 mediated pathway after UV-induced DNA damage. *J. Surg. Res.* 133, 29–37.

- Farrer, L.A., Cupples, L.A., Haines, J.L., Hyman, B., Kukull, W.A., Mayeux, R., Myers, R.H., Pericakvance, M.A., Risch, N., vanDuijn, C.M., 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease – a meta-analysis. *JAMA* 278, 1349–1356.
- Glatz, D.C., Rujescu, D., Tang, Y., Berendt, F.J., Hartmann, A.M., Faltraco, F., Rosenberg, C., Hulette, C., Jellinger, K., Hampel, H., Riederer, P., Moller, H.J., Andreadis, A., Henkel, K., Stamm, S., 2006. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. *J. Neurochem.* 96, 635–644.
- Gomez-Isla, T., Price, J.L., Mckeel, D.W., Morris, J.C., Growdon, J.H., Hyman, B.T., 1996. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. *J. Neurosci.* 16, 4491–4500.
- Guo, B., Zhai, D., Cabezas, E., Welsh, K., Nouraini, S., Satterthwait, A.C., Reed, J.C., 2003. Humanin peptide suppresses apoptosis by interfering with Bax activation. *Nature* 423, 456–461.
- Gutala, R.V., Reddy, P.H., 2004. The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains. *J. Neurosci. Methods* 132, 101–107.
- He, D.C., Nickerson, J.A., Penman, S., 1990. Core filaments of the nuclear matrix. *J. Cell Biol.* 110, 569–580.
- Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R.L., Atwood, C.S., Johnson, A.B., Kress, Y., Vinters, H.V., Tabaton, M., Shimohama, S., Cash, A.D., Siedlak, S.L., Harris, P.L., Jones, P.K., Petersen, R.B., Perry, G., Smith, M.A., 2001. Mitochondrial abnormalities in Alzheimer's disease. *J. Neurosci.* 21, 3017–3023.
- Manabe, T., Katayama, T., Sato, N., Gomi, F., Hitomi, J., Yanagita, T., Kudo, T., Honda, A., Mori, Y., Matsuzaki, S., Imaizumi, K., Mayeda, A., Tohyama, M., 2003. Induced HMG1a expression causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer's disease. *Cell Death Differ.* 10, 698–708.
- Mitchelmore, C., Buchmann-Moller, S., Rask, L., West, M.J., Troncoso, J.C., Jensen, N.A., 2004. NDRG2: a novel Alzheimer's disease associated protein. *Neurobiol. Dis.* 16, 48–58.
- Mitsui, K., Matsumoto, A., Ohtsuka, S., Ohtsubo, M., Yoshimura, A., 1999. Cloning and characterization of a novel p21(Cip1/Waf1)-interacting zinc finger protein, ciz1. *Biochem. Biophys. Res. Commun.* 264, 457–464.
- Morris, J.C., 1999. Clinical presentation and course of Alzheimer's disease. In: Terry, R.D., Katzman, R., Bick, K.L., Sisodia, S.S. (Eds.), *Alzheimer Disease*. Lippincott Williams & Wilkins, Philadelphia, pp. 11–24.
- Nagy, Z., 2000. Cell cycle regulatory failure in neurones: causes and consequences. *Neurobiol. Aging* 21, 761–769.
- Price, D.L., Sisodia, S.S., 1998. Mutant genes in familial Alzheimer's disease and transgenic models. *Annu. Rev. Neurosci.* 21, 479–505.
- Saunders, A.M., Schmechel, K., Breitner, J.C.S., Benson, M.D., Brown, W.T., Goldfarb, L., Goldgaber, D., Manwaring, M.G., Szymanski, M.H., Mccown, N., Dole, K.C., Schmechel, D.E., Strittmatter, W.J., Pericakvance, M.A., Roses, A.D., 1993. Apolipoprotein-E-epsilon4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. *Lancet* 342, 710–711.
- Sisodia, S.S., Thinakaran, G., Borchelt, D.R., Wong, P.C., Lee, M.K., Price, D.L., 1999. Function and dysfunction of the presenilins. In: Terry, R.D., Katzman, R., Bick, K.L., Sisodia, S.S. (Eds.), *Alzheimer Disease*. Lippincott Williams & Wilkins, Philadelphia, pp. 327–337.
- Terry, R.D., Masliah, E., Hansen, L.A., 1999. The neuropathology of Alzheimer disease and the structural basis of its cognitive alterations. In: Terry, R.D., Katzman, R., Bick, K.L., Sisodia, S.S. (Eds.), *Alzheimer Disease*. Lippincott Williams & Wilkins, Philadelphia, pp. 187–206.
- Vincent, I., Jicha, G., Rosado, M., Dickson, D.W., 1997. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. *J. Neurosci.* 17, 3588–3598.
- Wang, Z., Brown, D.D., 1991. A gene expression screen. *Proc. Natl. Acad. Sci. U. S. A.* 88, 11505–11509.
- Warder, D.E., Keherly, M.J., 2003. Ciz1, Cip1 interacting zinc finger protein 1 binds the consensus DNA sequence ARYSR(0-2)YYAC. *J. Biomed. Sci.* 10, 406–417.
- West, M.J., Coleman, P.D., Flood, D.G., Troncoso, J.C., 1994. Differences in the pattern of hippocampal neuronal loss in normal aging and Alzheimer's disease. *Lancet* 344, 769–772.
- Yang, Y., Geldmacher, D.S., Herrup, K., 2001. DNA replication precedes neuronal cell death in Alzheimer's disease. *J. Neurosci.* 21, 2661–2668.
- Yang, Y., Mufson, E.J., Herrup, K., 2003. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. *J. Neurosci.* 23, 2557–2563.
- Zhu, X., Perry, G., Moreira, P.I., Aliev, G., Cash, A.D., Hirai, K., Smith, M.A., 2006. Mitochondrial abnormalities and oxidative imbalance in Alzheimer disease. *J. Alzheimer's Dis.* 9, 147–153.